Posts tagged Sean Lavin
BTIG starts Organovo at buy

BTIG initiated coverage of Organovo Holdings (NASDAQ:ONVO) with a “buy” rating and $5 price target. The stock closed at $3.69 on Dec. 14.

Read More
Canaccord and BTIG start iRhythm at buy

BTIG initiated coverage of iRhythm Technologies (NASDAQ:IRTC) with a “buy” rating and a $28 price target. The stock closed at $24.23 on Friday.

iRhythm is a digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distil data from millions of heartbeats into clinically actionable information.

Read More
Analysts start Obalon Therapeutics at buy

Analysts at Stifel and BTIG initiated coverage of Obalon Therapeutics (NASDAQ:OBLN) with “buy” ratings and price targets of $18 and $20, respectively. The stock closed at $13.80 on Friday.

“Obalon appears poised for dramatic top-line growth with its highly-differentiated intragastric balloon system, already FDA-approved to treat 30-to-40 body mass index range obese patients,” writes Rick Wise of Stifel.

Read More
BTIG upgrades NeoGenomics to buy

BTIG upgraded NeoGenomics (NASDAQ:NEO) to “buy” from “neutral,” with a price target of $10, after the company reported third quarter results. The stock closed at $7.13 on Wednesday.

“When we downgraded shares at $9, our view was that a fair amount of good news had been priced into the stock – less draconian cuts to reimbursement, synergy capture of Clarient and continued share gains,” writes analyst Dr. Sean Lavin.

Read More
BTIG starts ViewRay at buy

BTIG Research launched coverage of ViewRay (NASDAQ:VRAY) with a “buy” rating and $6 price target. The stock closed at $3.58 on Tuesday.

MRIdian is the first commercial MRI guided radiation therapy treatment system available. “The image quality of the MRI is far superior to the imaging quality of the X-Ray and CT based systems today particularly with respect to soft-tissue cancers and anatomy,” writes analyst Dr. Sean Lavin.

Read More
Analysts start Tactile Systems at buy, outperform

Analysts at BTIG Research, Piper Jaffray and William Blair initiated coverage of Tactile Systems Technology (NASDAQ:TCMD) with “buy,” “overweight” and “outperform” ratings, respectively.

Tactile makes pneumatic compression devices (PCD) to treat lymphedema, along with a chronic venous leg ulcer product. Tactile closed an IPO of 4,120,000 shares at $10 apiece earlier this month. The stock was changing hands at $12.98 at mid-day Monday.

Read More
BTIG downgrades NeoGenomics to neutral

BTIG Research downgraded NeoGenomics (NASDAQ:NEO) to “neutral” from “buy.” The stock closed at $9.05 on Tuesday.

Analyst Dr. Sean Lavin writes that second quarter results were largely in-line. “The base business continues to trend well and with more clarity around Medicare in 2017, we think downside risk is fairly modest,” he said.

Read More
BTIG starts Insulet, Intersect at neutral

BTIG Research initiated research of Insulet (NASDAQ:PODD) and Intersect ENT (NASDAQ:XENT) with “neutral” ratings. Shares of Insulet closed at $32.21 and shares of Intersect at $13.51 on Tuesday.

Analyst Sean Lavin writes that he sees Insulet’s core business as fairly valued at five times next 12 months revenue as both the major upside events and key risks are hard to forecast in terms of timing. 

Read More
BTIG starts Entellus Medical at buy

BTIG Research has initiated coverage of Entellus Medical (NASDAQ:ENTL) with a ‘buy” rating and $22 price target. The stock closed at $18.58 on Monday.

“Entellus Medical benefits patients, physicians, and payers by moving balloon sinus dilation (BSD) out of the hospital and into physician offices,” writes analyst Dr. Sean Lavin.

Read More
BTIG starts Senseonics Holdings at buy

BTIG Research has launched coverage of Senseonics Holdings (NYSE MKT:SENS) with a “buy” rating and 12-month price target of $4.50. The stock closed at $2.97 on Monday.

“This may be a better way to monitor glucose if some hurdles are cleared,” writes analyst Dr. Sean Lavin, referring to the company’s implantable continuous glucose monitor (ICGM) and whether endocrinologists will be willing to do implants.

Read More